Master protocol to assess safety and recommended phase 2 dose of next generation NY-ESO-1-specific TCR T-cells in HLA-A*02 patients with synovial sarcoma or non-small cell lung cancer (Substudies 1 and 2) Meeting Abstract

  

Authors:	Schoenfeld, A. J.; Altan, M.; Owonikoko, T. K.; D'Angelo, S. P.; Ladle, B. H.; Noujaim, J. C.; He, K.; Liebner, D. A.; Sacher, A. G.; Haanen, J. B. A. G.; Yachnin, J.; Huang, C. H.; Van Tine, B. A.; Hasan, A. N.; Faitg, T. H.; Butler, E.; Shalabi, A.; Attia, S.; Araujo, D. M.
Abstract Title:	Master protocol to assess safety and recommended phase 2 dose of next generation NY-ESO-1-specific TCR T-cells in HLA-A*02 patients with synovial sarcoma or non-small cell lung cancer (Substudies 1 and 2)
Meeting Title:	2021 ASCO Annual Meeting
Journal Title:	Journal of Clinical Oncology
Volume:	39
Issue:	15 Suppl.
Meeting Dates:	2021 Jun 4-8
Meeting Location:	Virtual
ISSN:	0732-183X
Publisher:	American Society of Clinical Oncology
Date Published:	2021-05-20
Language:	English
ACCESSION:	WOS:000708120306200
DOI:	10.1200/JCO.2021.39.15_suppl.TPS2661
PROVIDER:	wos
Notes:	Meeting Abstract: TPS2661 -- Source: Wos

https://synapse.mskcc.org/synapse/works/has_related_data_chk/191290